Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Eli Lilly's Next Quarterly Earnings Report

Indianapolis, Indiana-based Eli Lilly and Company (LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the United States and internationally. The company has a market cap of $900.7 billion and offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, and more.

LLY is expected to release its Q1 2026 earnings on Thursday, Apr. 30, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $7.55 on a diluted basis, up 126.1% from $3.34 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in three of its...

Fundamentals

See More
  • Market Capitalization, $K 900,695,936
  • Shares Outstanding, K 944,819
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.51
  • Price/Sales 13.50
  • Price/Cash Flow 37.04
  • Price/Book 33.17

Options Overview Details

View History
  • Implied Volatility 43.59% (-0.11%)
  • Historical Volatility 32.48%
  • IV Percentile 85%
  • IV Rank 44.96%
  • IV High 64.05% on 04/10/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 1) 12.00 (1.25%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 23,148
  • Volume Avg (30-Day) 35,801
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 343,823
  • Open Int (30-Day) 323,537
  • Expected Range 951.34 to 975.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $7.55
  • Number of Estimates 8
  • High Estimate $8.56
  • Low Estimate $6.61
  • Prior Year $3.34
  • Growth Rate Est. (year over year) +126.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
877.11 +9.50%
on 03/27/26
1,012.00 -5.09%
on 03/10/26
-47.92 (-4.75%)
since 03/09/26
3-Month
877.11 +9.50%
on 03/27/26
1,114.00 -13.78%
on 02/04/26
-103.09 (-9.69%)
since 01/09/26
52-Week
623.78 +53.98%
on 08/08/25
1,133.95 -15.30%
on 01/08/26
+206.76 (+27.43%)
since 04/09/25

Most Recent Stories

More News
What to Expect From Eli Lilly's Next Quarterly Earnings Report

Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings.

XLV : 149.56 (-0.07%)
$SPX : 6,813.88 (+0.46%)
LLY : 957.35 (+0.42%)
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide

LLY : 957.35 (+0.42%)
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.

CEG : 286.99 (+0.96%)
NVO : 37.33 (-0.74%)
LLY : 957.35 (+0.42%)
CCL : 27.89 (-0.50%)
2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off

2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off

TTD : 20.27 (+0.10%)
LLY : 957.35 (+0.42%)
MCHP : 70.66 (-0.10%)
The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

NVDA : 183.40 (+0.72%)
$SPX : 6,813.88 (+0.46%)
CNTA : 39.74 (+0.53%)
LLY : 957.35 (+0.42%)
Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

NVO : 37.33 (-0.74%)
HIMS : 19.13 (-1.34%)
LLY : 957.35 (+0.42%)
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

CNTA : 39.74 (+0.53%)
LLY : 957.35 (+0.42%)
Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...

ALK : 39.74 (-0.43%)
MPC : 224.76 (-3.11%)
SNDK : 840.67 (+7.65%)
HL : 19.27 (-1.38%)
CDE : 19.56 (-0.81%)
LITE : 882.00 (-1.56%)
OXY : 58.76 (-1.69%)
NCNO : 17.63 (-0.62%)
GLW : 169.41 (+2.61%)
FANG : 187.56 (+0.58%)
STX : 498.68 (+0.48%)
WDC : 335.01 (-1.11%)
Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

LLY : 957.35 (+0.42%)
Eli Lilly (LLY) Stock Trades Up, Here Is Why

Eli Lilly (LLY) Stock Trades Up, Here Is Why

LLY : 957.35 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 993.25
2nd Resistance Point 977.19
1st Resistance Point 965.25
Last Price 957.35
1st Support Level 937.24
2nd Support Level 921.18
3rd Support Level 909.24

See More

52-Week High 1,133.95
Last Price 957.35
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.